Autolus Therapeutics (NASDAQ:AUTL) Reaches New 12-Month Low – What’s Next?

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $1.86 and last traded at $1.88, with a volume of 258277 shares changing hands. The stock had previously closed at $1.95.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Friday, November 15th. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, January 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Autolus Therapeutics has an average rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Trading Down 4.8 %

The stock has a market cap of $476.30 million, a price-to-earnings ratio of -1.48 and a beta of 2.02. The business has a 50 day simple moving average of $2.20 and a two-hundred day simple moving average of $3.16.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. increased its stake in Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock valued at $139,000 after buying an additional 14,959 shares during the period. Privium Fund Management B.V. grew its stake in Autolus Therapeutics by 15.6% in the third quarter. Privium Fund Management B.V. now owns 185,639 shares of the company’s stock valued at $674,000 after purchasing an additional 25,000 shares in the last quarter. GSA Capital Partners LLP bought a new position in Autolus Therapeutics during the third quarter valued at approximately $1,082,000. HealthInvest Partners AB raised its holdings in shares of Autolus Therapeutics by 95.6% during the 3rd quarter. HealthInvest Partners AB now owns 442,423 shares of the company’s stock valued at $1,606,000 after purchasing an additional 216,278 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after acquiring an additional 5,478,706 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.